Xu Lan-Ping, Lu Pei-Hua, Wu De-Pei, Huang He, Jiang Er-Lie, Liu Dai-Hong, Cao Wei-Jie, Zhang Xi, Fu Yue-Wen, Li Nai-Nong, Chen Xin-Chuan, Zhu Xiao-Yu, Liu Qi-Fa, Xia Ling-Hui, Zhang Yi-Cheng, Xu Ya-Jing, Li Fu-Chun, Hu Jiong, Liu Si-Xi, Liu Rong-Rong, Ma Xiao-Di, Tang Xiao-Wen, Luo Yi, Zhang Xiao-Hui, Huang Xiao-Jun
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Hebei Yanda Lu Daopei Hospital, Langfang, Hebei & Beijing Lu Daopei Hospital, Beijing, China.
Bone Marrow Transplant. 2024 Dec;59(12):1726-1734. doi: 10.1038/s41409-024-02419-8. Epub 2024 Sep 25.
Over past two years, a total of 39,918 hematopoietic stem cell transplantation (HSCT) cases were reported, with 18,194 and 21,714 transplants performed in 2022 and 2023, respectively. Autologous HSCT accounted for 6562 cases (31%) in 2022, while allogeneic HSCT comprised 12,632 cases (69%). In 2023, the number of allogeneic HSCTs exceeded 15,000, maintaining a 69% share. Participation in the 2022 and 2023 surveys included 193 and 212 transplantation teams, respectively, from 27 provinces, municipalities, or autonomous regions. The leading indication of HSCT was acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and mixed phenotype acute leukemia, with a total of 17,421 cases. AML was the most common disease (10,339, 38%) for allogeneic HSCT, which was followed by ALL (5925 cases, 21%). Peripheral blood emerged as the primary source of stem cell grafts, utilized in 54% of matched sibling donor transplants and 77% of haploidentical donor transplants. The BuCy-based conditioning regimen was the most prevalent, used in 53% of allogeneic HSCT cases in the past two years. This survey offers a comprehensive overview of the current HSCT landscape and serves as a valuable resource for clinical practice.
在过去两年中，共报告了39918例造血干细胞移植（HSCT）病例，2022年和2023年分别进行了18194例和21714例移植。2022年自体HSCT占6562例（31%），而异基因HSCT包括12632例（69%）。2023年，异基因HSCT的数量超过15000例，占比维持在69%。参与2022年和2023年调查的分别有来自27个省、直辖市或自治区的193个和212个移植团队。HSCT的主要适应症是急性白血病，包括急性髓系白血病（AML）、急性淋巴细胞白血病（ALL）和混合表型急性白血病，共有17421例。AML是异基因HSCT最常见的疾病（10339例，38%），其次是ALL（5925例，21%）。外周血成为干细胞移植物的主要来源，在54%的同胞全相合供体移植和77%的单倍体相合供体移植中使用。基于白消安-环磷酰胺的预处理方案最为普遍，在过去两年中用于53%的异基因HSCT病例。本次调查全面概述了当前HSCT的情况，是临床实践的宝贵资源。
